Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET(TM) Immunotherapy Drug Candidates

Celgene licenses two TriNKET™ immunotherapy drug candidates built by Dragonfly for $24m plus milestones and royalties WALTHAM, Mass., Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the ... Biopharmaceuticals, Oncology, Licensing Dragonfly Therapeutics, Celgene, TriNKET, Immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news